Pharmacokinetics of Buprenorphine Buccal Film and Orally-administered Oxycodone in a Respiratory Study: An Analysis of Secondary Outcomes from a Randomized Controlled Trial
ConclusionThese results indicate that BBF may have a decreased risk of abuse and respiratory depression compared with the full µ-opioid receptor agonist oxycodone.Trial RegistrationClinicalTrials.gov identifier, NCT03996694.
Source: Pain and Therapy - Category: Anesthesiology Source Type: research
More News: Anesthesiology | Depression | Oxycodone | OxyContin | Pain | Respiratory Medicine | Study | Substance Abuse